source: internationalization/trunk/TranslationSpreadsheets/WV-DIALOG-0247.txt@ 909

Last change on this file since 909 was 604, checked in by George Lilly, 15 years ago

Internationalization

File size: 13.0 KB
Line 
1English French Notes Complete/Exclude
225. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY
326. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY
418. BEHAVIOR CODE (ICD-O-2)
5 10. CLASS OF CASE................:
6 11. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
7659 LOWER BACK PAIN..............
8660 TROUBLE URINATING............
9 12. INITIAL METHOD OF DIAGNOSIS:
10661 CLINICAL DX WITH BONE LESION.
11662 CLINICAL DX BY RECTAL EXAM...
12664 DIGITAL TRANSRECTAL BIOPSY...
13665 INCIDENTAL FINDING IN TURP FOR BENIGN DISEASE...........
14666 NEEDLE BIOPSY, NOS...........
15667 PERINEAL BIOPSY..............
16669 TRUS GUIDED BIOPSY...........
17 13. DIAGNOSTIC EVALUATION:
18671 BONE MARROW ASPIRATION.......
19672 BONE SCAN....................
20675 CT SCAN OF ABDOMEN...........
21676 CT SCAN OF PELVIS............
22679 PELVIC LYMPH NODE DISSECTION.
23683 ULTRASOUND OF ABDOMEN........
24684 14. RESULTS OF MOST RECENT PRE- TREATMENT PSA TEST...........
25 16. PRIMARY SITE (ICD-O-2).......: C61.9
26 18. BEHAVIOR CODE (ICD-O-2)......:
27141 20. BIOSPY PROCEDURE.............
28 21. GUIDANCE OF BIOPSY TO PRIMARY: Not guided, no biopsy
29 22. BIOPSY APPROACH FOR PRIMARY..: No biopsy
30 21. GUIDANCE OF BIOPSY TO PRIMARY: Unknown/death cert only
31 22. BIOPSY APPROACH FOR PRIMARY..: Unknown/death cert only
32142 21. GUIDANCE OF BIOSPY TO PRIMARY
33145 22. BIOSPY APPROACH FOR PRIMARY..
34146 23. BIOSPY OF OTHER THAN PRIMARY.
3526 24. DIAGNOSTIC CONFIRMATION......
36 25. GLEASON'S SCORE FOR BIOPSY, LOCAL RESECTION, OR SIMPLE PROSTATECTOMY:
37 Surgery codes not 02 through 40
38 GLEASON SCORE................: 99 Unknown, not reported, or NA
39 GLEASON SCORE................:
40623 GLEASON SCORE................
41 26. GLEASON'S SCORE FOR RADICAL PROSTATECTOMY:
42 Surgery codes not 50 through 70
43623.3 GLEASON SCORE................
4427. SIZE OF TUMOR (mm)
4528. REGIONAL NODES EXAMINED
4629. REGIONAL NODES POSITIVE
4730. AJCC CLINICAL STAGE (cTNM)
4831. AJCC PATHOLOGIC STAGE (pTNM)
4932. STAGED BY
50 TABLE III - EXTENT AND STAGE OF DISEASE
5129 27. SIZE OF TUMOR (mm).....
5233 28. REGIONAL NODES EXAMINED
5332 29. REGIONAL NODES POSITIVE
54 30. AJCC CLINICAL STAGE (cTNM):
55 31. AJCC PATHOLOGIC STAGE (pTNM):
56 32. STAGED BY:
5719 CLINICAL STAGE.........
5889 PATHOLOGIC STAGE.......
59 33. DATE OF FIRST COURSE TREATMENT.:
60685 34. EXPECTED MGT/WATCHFUL WAITING..
61 35. DATE OF NON CA-DIRECTED SURGERY:
62 36. NON CANCER-DIRECTED SURGERY....:
63 37. DATE OF CANCER-DIRECTED SURGERY:
64 38. LENGTH OF STAY AFTER SURGERY...: 88 NA
65 38. LENGTH OF STAY AFTER SURGERY...: 99 Unknown
66686 38. LENGTH OF STAY AFTER SURGERY...
67 39. SURGICAL APPROACH..............:
68 40. TYPE OF CANCER-DIRECTED SURGERY:
69 41. SURGICAL MARGINS...............:
70 42. SCOPE OF LYMPH NODE SURGERY....:
71 43. TYPE OF LYMPH NODE SURGERY:
72 44. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
73 OR DISTANT LYMPH NODE(S).......:
74 45. NUMBER OF LYMPH NODES REMOVED..:
75 47. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:
76 PERMANENT RECTAL INJURY........: NA, no surgery
77 THROMBOEMBOLISM................: NA, no surgery
78 URETHRAL STRICTURE.............: NA, no surgery
79 48. POSTOPERATIVE DEATH W/I 30 DAYS: NA, no surgery
80 PERMANENT RECTAL INJURY........: Unknown
81 URETHRAL STRICTURE.............: Unknown
82 48. POSTOPERATIVE DEATH W/I 30 DAYS: Unknown
83689 PERMANENT RECTAL INJURY........
84691 URETHRAL STRICTURE.............
85441 48. POSTOPERATIVE DEATH W/I 3O DAYS
86 49. DATE RADIATION STARTED.........:
87 50. RADIATION THERAPY..............:
88 51. RADIATION FACILITY.............:
89 52. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:
90 OTHER INTERSTITIAL, NOS........:
91 53. ROUTE OF INTERSTITIAL RADIATION/
92 BRACHYTHERAPY ADMINISTERED.....:
93 54. EXTERNAL RADIATION ADMINISTERED:
94 DISTANT METASTATIC SITES.......:
95 PROSTATE & PELVIC NODES........:
96 PROSTATE & PARA-AORTIC NODES...:
97 PROSTATE REGION ONLY...........:
98 OTHER EXTERNAL SITES, NOS......:
99 55. TYPE OF EXTERNAL RADIATION
100 56. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:
101 PELVIC NODES...................:
102 PARA-AORTIC NODES..............:
103 57. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:
104 ACUTE GASTROINTESTINAL.........:
105 ACUTE GASTROURINARY............:
106 CHRONIC REQUIRING SURGERY OR
107 PROLONGED HOSPITALIZATION......:
108 URETHRAL OR BLADDER............:
109692 51. RADIATION FACILITY.............
110631 OTHER INTERSTITIAL, NOS........
111693 53. ROUTE OF INTERSTITIAL RADIATION/ BRACHYTHERAPY ADMINISTERED.....
112636 DISTANT METASTATIC SITES.......
113634 PROSTATE & PELVIC NODES........
114635 PROSTATE & PARA-AORTIC NODES...
115633 PROSTATE REGION ONLY...........
116637 OTHER EXTERNAL SITES, NOS......
117694 55. TYPE OF EXTERNAL RADIATION ADMINISTRATION.................
118639 PELVIC NODES...................
119640 PARA-AORTIC NODES..............
120695 ACUTE GASTROINTESTINAL.........
121696 ACUTE GASTROURINARY............
122698 CHRONIC REQUIRING SURGERY OR PROLONGED HOSPITALIZATION......
123699 URETHRAL OR BLADDER............
124 58. DATE OF ORCHIECTOMY............: 00/00/0000
125699.1 58. DATE OF ORCHIECTOMY............
126 59. DATE EXOGENOUS HT BEGAN........:
127 60. HORMONE THERAPY................:
128 61. EXOGENOUS HORMONE AGENTS ADMINISTERED:
129 LUTEINIZING HORMONES...........:
130 PROGESTATIONAL AGENTS..........:
131646 LUTEINIZING HORMONES...........
132645 PROGESTATIONAL AGENTS..........
133 62. DATE CHEMOTHERAPY STARTED......:
13464. DATE OF FIRST RECURRENCE
13565. TYPE OF FIRST RECURRENCE
13664. TYPE OF FIRST RECURRENCE
13765. DATE OF FIRST RECURRENCE
13870 64. DATE OF FIRST RECURRENCE
13971 65. TYPE OF FIRST RECURRENCE
14066. DATE OF LAST CONTACT OR DEATH
14167. VITAL STATUS
14268. CANCER STATUS
14369. COMPLETED BY
14470. CLINICAL REVIEW BY CA COMMITTEE
145 66. DATE OF LAST CONTACT OR DEATH..:
14615 67. VITAL STATUS...................
147 68. CANCER STATUS..................:
14881 69. COMPLETED BY...................
14982 70. CLINICAL REVIEW BY CA COMMITTEE
150 8. PRIMARY PAYER AT DIAGNOSIS.......:
151 9. FAMILY HISTORY OF PROSTATE CANCER:
15210. CLASS OF CASE....................:
15311. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
154 LOWER BACK PAIN.................:
155 TROUBLE URINATING...............:
15612. INITIAL METHODS OF DIAGNOSIS:
157 CLINICAL DX W BONE LESION.......:
158 CLINICAL DX BY RECTAL EXAM......:
159 DIGITAL TRANSRECTAL BIOPSY......:
160 INCIDENTAL FINDING IN TURP FOR BENIGN DISEASE..................:
161 NEEDLE BIOPSY, NOS..............:
162 PERINEAL BIOPSY.................:
163 TRUS GUIDED BIOPSY..............:
16413. DIAGNOSTIC EVALUATION:
165 BONE MARROW ASPIRATION..........:
166 BONE SCAN.......................:
167 CT SCAN OF ABDOMEN..............:
168 CT SCAN OF PELVIS...............:
169 PELVIC LYMPH NODE DISSECTION....:
170 ULTRASOUND OF ABDOMEN...........:
17114. RESULTS OF MOST RECENT PRE-
172 TREATMENT PSA TEST...............:
17315. DATE OF INITIAL DIAGNOSIS........:
17416. PRIMARY SITE (ICD-O-2)...........:
17518. BEHAVIOR CODE (ICD-O-2)..........:
17620. BIOPSY PROCEDURE.................:
17721. GUIDANCE OF BIOPSY TO PRIMARY....:
17822. BIOPSY APPROACH FOR PRIMARY......:
17923. BIOPSY OF OTHER THAN PRIMARY.....:
18024. DIAGNOSTIC CONFIRMATION..........:
181 GLEASON SCORE...................:
18227. SIZE OF TUMOR (mm)...............:
18328. REGIONAL NODES EXAMINED..........:
18429. REGIONAL NODES POSITIVE..........:
18530. AJCC CLINICAL STAGE (cTNM):
18631. AJCC PATHOLOGIC STAGE (pTNM):
18732. STAGED BY:
18833. DATE OF FIRST COURSE TREATMENT...:
18934. EXPECTED MGT/WATCHFUL WAITING....:
19035. DATE OF NON CA-DIRECTED SURGERY..:
19136. NON CANCER-DIRECTED SURGERY......:
19237. DATE OF CANCER-DIRECTED SURGERY..:
19338. LENGTH OF STAY AFTER SURGERY.....:
19439. SURGICAL APPROACH................:
19540. TYPE OF CANCER-DIRECTED SURGERY..:
19641. SURGICAL MARGINS.................:
19742. SCOPE OF LYMPH NODE SURGERY......:
19843. TYPE OF LYMPH NODE SURGERY:
19944. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
20045. NUMBER OF LYMPH NODES REMOVED....:
20147. COMPLICATIONS FOLLOWING SURGICAL FIRST COURSE OF TREATMENT:
202 PERMANENT RECTAL INJURY.........:
203 URETHRAL STRICTURE..............:
20448. POSTOPERATIVE DEATH W/I 30 DAYS..:
20549. DATE RADIATION STARTED...........:
20650. RADIATION THERAPY................:
20751. RADIATION FACILITY...............:
20852. INTERSTITIAL RADIATION/BRACHYTHERAPY ADMINISTERED:
209 OTHER INTERSTITIAL, NOS.........:
21053. ROUTE OF INTERSTITIAL RADIATION/
211 BRACHYTHERAPY ADMINISTERED.......:
21254. EXTERNAL RADIATION ADMINISTERED:
213 DISTANT METASTATIC SITES........:
214 PROSTATE & PELVIC NODES.........:
215 PROSTATE & PARA-AORTIC NODES....:
216 PROSTATE REGION ONLY............:
217 OTHER EXTERNAL SITES, NOS.......:
21855. TYPE OF EXTERNAL RADIATION
21956. TOTAL EXTERNAL RAD DOSE (cGy) INCLUDING BOOST:
220 PELVIC NODES....................:
221 PARA-AORTIC NODES...............:
22257. COMPLICATIONS FOLLOWING RADIATION FIRST COURSE OF TREATMENT:
223 ACUTE GASTROINTESTINAL..........:
224 ACUTE GASTROURINARY.............:
225 PROLONGED HOSPITALIZATION.......:
226 URETHRAL OR BLADDER.............:
22758. DATE OF ORCHIECTOMY.............:
22859. DATE EXOGENOUS HT BEGAN.........:
22960. HORMONE THERAPY.................:
23061. EXOGENOUS HORMONE AGENTS ADMINISTERED:
231 LUTEINIZING HORMONES............:
232 PROGESTATIONAL AGENTS...........:
23362. DATE CHEMOTHERAPY STARTED........:
23464. DATE OF FIRST RECURRENCE.........:
23565. TYPE OF FIRST RECURRENCE.........:
23666. DATE OF LAST CONTACT OR DEATH....:
23767. VITAL STATUS.....................:
23868. CANCER STATUS....................:
23969. COMPLETED BY.....................:
24070. REVIEWED BY CANCER COMMITTEE.....:
241ROADS TO FORDS
2427 PLACE OF BIRTH.............
2439 SPANISH ORIGIN.............//^S X=
244Non-Spanish, non-Hispanic
24548 AGENT ORANGE EXPOSURE......//^S X=AOE
24650 IONIZING RADIATION EXPOSURE//^S X=IRE
24752 CHEMICAL EXPOSURE..........
24861 ASBESTOS EXPOSURE..........
24951 PERSIAN GULF SERVICE.......//^S X=PGS
25055 MIDDLE EAST SERVICE........//^S X=MES
25156 SOMALIA SERVICE............//^S X=SS
252 Reporting Hospital..........:
253 Marital status at Dx........:
254 Patient address at Dx.......:
255 Patient address at Dx - Supp:
256 City/town at Dx.............:
257 State at Dx.................:
258 Postal code at Dx...........:
259 County at Dx................:
260 Census Tract................:
261 Following physician.........:
262 Primary surgeon.............:
263 Primary payer at Dx.........:
264 Type of reporting source....:
265 Class of Case................:
266 Facility referred from.......:
267 Facility referred to.........:
268 Date of First Contact........:
269 Date Dx......................:
270 Dx Facility..................:
271 Histology/Behavior Code......:
272 AFIP submission..............:
273 Diagnostic Confirmation......:
274 Presentation at Cancer Conf..:
275 Place of birth.............:
276 Spanish origin.............:
277 Agent Orange exposure......:
278 Ionizing radiation exposure:
279 Chemical exposure..........:
280 Asbestos exposure..........:
281 Persian Gulf service.......:
282 Middle East service........:
283 Somalia service............:
284 Usual Occupation...........:
285 Usual Industry.............:
286 Tobacco History............:
287 Alcohol History............:
288 Family History of Cancer...:
289 Family Member with Cancer..:
290 PREVIOUS HISTORY OF CANCER
291 Previous History of Cancer.....:
2921///Unknown if BRM therapy administered
293Patient Care Evaluation Studies of Cancer of the Prostate
294DATE OF ADMISSION
295ACCESSION/SEQUENCE NUMBER.:
296CLASS OF CASE.............:
2979ZIP CODE..................
298BIRTHDATE.................:
29918PRIMARY PAYER AT DIAGNOSIS
3001DATE OF ADMISSION.........
3011.1DATE OF DISCHARGE.........
302METHOD OF DIAGNOSIS
303#################### #################### ####################
304#################### #################### ####################
305#################### #################### ####################
306#################### #################### ####################
307#################### #################### ####################
Note: See TracBrowser for help on using the repository browser.